Hitachi and University of Utah Health develop a new AI pathway for chronic pain patients who require complex medicine

Hitachi has partnered with the University of Utah Health and the nonprofit health data research team Regenstrief Institute to develop and test a new AI approach that supports the management of patients with type 2 diabetes. measuring hard medicine.


In one study, the AI ​​history analyzed EHR data in Utah and Indiana in the United States and studied common treatment modalities and treatment outcomes among type 2 diabetes patients with similar conditions. . It then reorganizes patients into patient state groups and predicts a range of health outcomes related to treatment choices.

According to a press release, the algorithm can support the selection of medications in over 83% of patients, even when two medications are used.

One of the The findings of this study were published in the peer -reviewed medical journal, Journal of Biomedical Informatics.

Why it is

More than 500 million people worldwide are at risk of developing type 2 diabetes, according to the latest figures from the International Diabetes Federation. A small minority of them, Hitachi said, require more medications to control blood sugar and prevent serious problems such as loss of consciousness and disease. Their physicians may have limited experience in guiding the evidence for selecting drug combinations and making the right treatment decision.

The features learned by the new AI technology developed by Hitachi and its partners can be used to help doctors decide on the best treatment for a chronic disease.

In a statement, the research team behind this technology said they wanted to help diabetics who require critical care get the right medical plan from their doctors after undergoing a checkup. the benefit of different drug companies. “This will not only lead to better diabetes management but increase patient engagement, performance, and quality of life,” they added.

The partners said they will continue to evaluate and improve the quality of their AI and accelerate its potential application by partnering with healthcare professionals and R&D teams.


Hitachi has been working with U Health since 2018 to develop a drug selection system for the management of diabetes. The system they developed could not accurately predict the more complex or less complex types of drugs due to insufficient data. That’s why they teamed up with Regenstrief, a research group affiliated with Indiana University, to explore the value of health data.

In recent years, additional AI devices have been approved for diabetes management. Bigfoot Biomedical, a medtech startup in California, was cleaned last year by the U.S. Food and Drug Administration for its diabetes management system that provides insulin advice for diabetic users under traditional medicine.

Israel begins DreaMed has also received FDA approval for its AI-enabled diabetes care provider that treats patients with type 2 diabetes. The Advisor Pro Al Clinical Decision Support System helps providers manage insulin requirements. of their patients and monitor their blood sugar levels using regular glucose monitors.

Related Posts

Leave a Reply

Your email address will not be published.